Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFATC1 | O95644 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468033 | 1.00 | IMPDH2 (0.41) | IMPDH2GAAGOT1AXLEP300 | |
| SCHEMBL25857239 | 0.85 | MAPT (0.35) | IMPDH2GAAGOT1AXLEP300 | |
| SCHEMBL24575364 | 0.85 | IMPDH2 (0.43) | IMPDH2GAAGOT1AXLEP300 | |
| SCHEMBL16274537 | 0.85 | IMPDH2 (0.35) | IMPDH2GAAAXLEP300KAT2B | |
| SCHEMBL25254434 | 0.85 | EP300 (0.40) | IMPDH2GAAAXLEP300KAT2B | |
| SCHEMBL24575366 | 0.85 | IMPDH2 (0.43) | IMPDH2GAAGOT1AXLEP300 | |
| SCHEMBL31197276 | 0.85 | EP300 (0.40) | IMPDH2GAAAXLEP300KAT2B | |
| SCHEMBL30771962 | 0.85 | IMPDH2 (0.43) | IMPDH2GAAGOT1AXLEP300 | |
| SCHEMBL24379642 | 0.80 | GOT1 (0.41) | IMPDH2GAAGOT1CHUKMAPT | |
| SCHEMBL31306384 | 0.80 | GOT1 (0.62) | IMPDH2GAAGOT1AXLEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735433-A2 | SUBSTITUTED PYRIDAZINE COMPOUNDS AS INHIBITORS OF NLRP3 ACTIVITY AND THERAPEUTIC USES THEREOF | Viva Star Biosciences (US) Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4320102-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | VENTUS THERAPEUTICS U S INC (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | TAKEDA DEVELOPMENT CENTER AMERICAS, INC. | 2025-11-06 | — | — | US | disclosed |
| EP-4644380-A1 | PYRIDAZINE NLRP3 INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| US-8222251-B2 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2012-07-17 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012000595-A1 | 2,4- DIARYL - SUBSTITUTED [1,8] NAPHTHYRIDINES AS KINASE INHIBITORS FOR USE AGAINST CANCER | MERCK PATENT GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-2188283-A1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | Amgen Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009035568-A1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009035568-A1 | ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING | AMGEN INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099173-A1 | Pyridopyridazine compounds, compositions and methods of use | DPYD, CYP3A5, PNPO | IMPDH2 274/4885GAA 1498/4885GOT1 1257/4885 |
| US-20260042757-A1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NLRP3 | NLRP3, NLRP1, PYCARD | IMPDH2 3439/4885GAA 3894/4885GOT1 1958/4885 |
| US-20250340563-A1 | FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS | NLRP3, NLRP1, NOD1 | IMPDH2 3982/4885GAA 2702/4885GOT1 1771/4885 |
| US-12441728-B2 | Pyridazine compounds for inhibiting NLRP3 | NLRP3, NLRP1, NOD1 | IMPDH2 1542/4885GAA 1882/4885GOT1 293/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | IMPDH2 3134/4885GAA 2173/4885GOT1 866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.